Technical Name 變種冠狀病毒蛋白晶片:疫情與後疫情時代之應用
Project Operator National cheng kung university
Project Host 許觀達
Summary Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.
Technical Film
Scientific Breakthrough The coronavirus protein microarray is originally designedfabricated by our team in NCKU with the following innovations:1. Patent-protected protein array design to allow high performance.2. Special array coating to allow a better signal-to-noise ratiolimit of detection.3. Ability to massive production. We can produce protein arrays with minimal batch variations.4. Unique assay procedures. We use a unique blocking buffer that can reduce the assay duration by 10 fold.5. AI-empowered analysis. We developed an AI tool to directly analyze the raw imagequickly generate the report.\"
Industrial Applicability There is no product that has multiple SARS-CoV-2 variants in the market but two similar wild-type products with no evidence of receptor bindings. We plan to vertical integrate the chip coating, protein array fabrication, data analysis,part of the sales. Also, we plan to outsource some of the protein purificationthe laser scanner to some companies in Taiwan. As for the foreign market, we have nonexclusive tech transferred our array to the world's largest protein microarray company for sales in North American. Therefore, we have connected the vertical chainsdeployed the world.
Matching Needs 1.欲媒合之產業領域:生技醫藥。2.欲媒合項目:技術合作、技術轉移、技術協助、生產製造、供應商尋找、投資合作。
Keyword High throughput Protein microarray Coronavirus SARS-CoV-2 COVID-19 Immunoglobulin Antigen Blood Variant Drug screening
Notes
  • Contact
  • 許觀達